152 related articles for article (PubMed ID: 38247364)
1. The efficacy and safety of low-dose rituximab in the treatment of pemphigus vulgaris: a cohort study.
Zhou X; Zhan T; Xu X; Lan T; Hu H; Zhou Y; Xia D; Wang J; Wang Y; Xiao Y; Li W
J Dermatolog Treat; 2024 Dec; 35(1):2302071. PubMed ID: 38247364
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of biosimilar rituximab in patients with pemphigus vulgaris: a prospective observational study.
Toosi R; Mahmoudi H; Balighi K; Teimourpour A; Alaeen H; Shaghaghi M; Abedini R; Daneshpazhooh M
J Dermatolog Treat; 2021 Feb; 32(1):33-40. PubMed ID: 31074302
[No Abstract] [Full Text] [Related]
3. Rituximab is an effective treatment in patients with pemphigus vulgaris and demonstrates a steroid-sparing effect.
Chen DM; Odueyungbo A; Csinady E; Gearhart L; Lehane P; Cheu M; Maho-Vaillant M; Prost-Squarcioni C; Hebert V; Houivet E; Calbo S; Caillot F; Golinski ML; Labeille B; Picard-Dahan C; Paul C; Richard MA; Bouaziz JD; Duvert-Lehembre S; Bernard P; Caux F; Alexandre M; Ingen-Housz-Oro S; Vabres P; Delaporte E; Quereux G; Dupuy A; Debarbieux S; Avenel-Audran M; D'Incan M; Bedane C; Bénéton N; Jullien D; Dupin N; Misery L; Machet L; Beylot-Barry M; Dereure O; Sassolas B; Benichou J; Musette P; Joly P;
Br J Dermatol; 2020 May; 182(5):1111-1119. PubMed ID: 31487383
[TBL] [Abstract][Full Text] [Related]
4. Comparing early and late treatments with rituximab in pemphigus vulgaris: which one is better?
Balighi K; Daneshpazhooh M; Mahmoudi H; Badakhsh M; Teimourpour A; Ehsani AH; Azizpour A; Akbari Z; Mahdavinia M; Ghasemiadl M; Tavakolpour S
Arch Dermatol Res; 2019 Jan; 311(1):63-69. PubMed ID: 30506422
[TBL] [Abstract][Full Text] [Related]
5. First line treatment of pemphigus vulgaris with a novel protocol in patients with contraindications to systemic corticosteroids and immunosuppressive agents: Preliminary retrospective study with a seven year follow-up.
Ahmed AR; Nguyen T; Kaveri S; Spigelman ZS
Int Immunopharmacol; 2016 May; 34():25-31. PubMed ID: 26919279
[TBL] [Abstract][Full Text] [Related]
6. Rituximab in practice: Clinical evaluation of patients with pemphigus after rituximab administration.
Mahmoudi H; Tavakolpour S; Balighi K; Farid AS; Nili A; Jan D; Daneshpazhooh M
Dermatol Ther; 2021 Jan; 34(1):e14633. PubMed ID: 33280226
[TBL] [Abstract][Full Text] [Related]
7. Iranian guideline for rituximab therapy in pemphigus patients.
Daneshpazhooh M; Balighi K; Mahmoudi H; Tavakolpour S; Abedini R; Soori T; Ehsani AH; Ghiasi M; Noormohammadpour P; Ghandi N; Lajevardi V; Sadeghinia A; Nasimi M; Azizpour A; Chams-Davatchi C
Dermatol Ther; 2019 Sep; 32(5):e13016. PubMed ID: 31269316
[TBL] [Abstract][Full Text] [Related]
8. Current biologics in treatment of pemphigus foliaceus: a systematic review.
Carver CA; Kalesinskas M; Ahmed AR
Front Immunol; 2023; 14():1267668. PubMed ID: 37901249
[TBL] [Abstract][Full Text] [Related]
9. Rituximab and low dose oral immune modulating treatment to maintain a sustained response in severe pemphigus patients.
Keeley JM; Bevans SL; Jaleel T; Sami N
J Dermatolog Treat; 2019 Jun; 30(4):340-345. PubMed ID: 30086663
[No Abstract] [Full Text] [Related]
10. Efficacy and safety of adjuvant immunoadsorption in pemphigus vulgaris and pemphigus foliaceus (IA-Pem Study): a multicentre randomized controlled trial.
van Beek N; Eming R; Reuss A; Zillikens D; Sárdy M; Günther C; Kiritsi D; Benoit S; Beissert S; Gläser R; Gollnick H; Horváth ON; Pfeiffer C; Röcken M; Schauer F; Schreml S; Steinbrink K; Zink A; Schade-Brittinger C; Hertl M; Schmidt E
Br J Dermatol; 2024 Apr; 190(5):657-667. PubMed ID: 38133541
[TBL] [Abstract][Full Text] [Related]
11. Unexpected worsening of pemphigus vulgaris after rituximab: A report of three cases.
Mahmoudi H; Balighi K; Tavakolpour S; Daneshpazhooh M
Int Immunopharmacol; 2019 Jun; 71():40-42. PubMed ID: 30877872
[TBL] [Abstract][Full Text] [Related]
12. The evolving role of rituximab in the treatment of pemphigus vulgaris: a comprehensive state-of-the-art review.
Kridin K; Ahmed AR
Expert Opin Biol Ther; 2021 Apr; 21(4):443-454. PubMed ID: 33455475
[TBL] [Abstract][Full Text] [Related]
13. Sustained Remission Without Corticosteroids Among Patients With Pemphigus Who Had Rituximab as First-Line Therapy: Follow-Up of the Ritux 3 Trial.
Tedbirt B; Maho-Vaillant M; Houivet E; Mignard C; Golinski ML; Calbo S; Prost-Squarcioni C; Labeille B; Picard-Dahan C; Chaby G; Richard MA; Tancrede-Bohin E; Duvert-Lehembre S; Delaporte E; Bernard P; Caux F; Alexandre M; Musette P; Ingen-Housz-Oro S; Vabres P; Quereux G; Dupuy A; Debarbieux S; Avenel-Audran M; D'Incan M; Bédane C; Bénéton N; Jullien D; Dupin N; Misery L; Machet L; Beylot-Barry M; Dereure O; Sassolas B; Benichou J; Joly P; Hébert V;
JAMA Dermatol; 2024 Mar; 160(3):290-296. PubMed ID: 38265821
[TBL] [Abstract][Full Text] [Related]
14. Rituximab therapy in pediatric pemphigus patients: A retrospective analysis of five Turkish patients and review of the literature.
Bilgic-Temel A; Özgen Z; Harman M; Kapıcıoğlu Y; Uzun S
Pediatr Dermatol; 2019 Sep; 36(5):646-650. PubMed ID: 31355479
[TBL] [Abstract][Full Text] [Related]
15. Rituximab in childhood and juvenile autoimmune bullous diseases as first-line and second-line treatment: a case series of 13 patients.
Kianfar N; Dasdar S; Mahmoudi H; Tavakolpour S; Balighi K; Daneshpazhooh M
J Dermatolog Treat; 2022 Mar; 33(2):869-874. PubMed ID: 32589481
[TBL] [Abstract][Full Text] [Related]
16. Multiple cycles of rituximab therapy for pemphigus: A group of patients with difficult- to-treat disease or a consequence of late rituximab initiation?
Balighi K; Hatami P; Sheikh Aboli MJ; Daneshpazhooh M; Ghiasi M; Mahmoudi HR; Aryanian Z
Dermatol Ther; 2022 Feb; 35(2):e15249. PubMed ID: 34910350
[TBL] [Abstract][Full Text] [Related]
17. A systematic review on efficacy, safety, and treatment-durability of low-dose rituximab for the treatment of Pemphigus: special focus on COVID-19 pandemic concerns.
Tavakolpour S; Aryanian Z; Seirafianpour F; Dodangeh M; Etesami I; Daneshpazhooh M; Balighi K; Mahmoudi H; Goodarzi A
Immunopharmacol Immunotoxicol; 2021 Oct; 43(5):507-518. PubMed ID: 34287098
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of rituximab for pemphigus: a systematic review and meta-analysis of different regimens.
Wang HH; Liu CW; Li YC; Huang YC
Acta Derm Venereol; 2015 Nov; 95(8):928-32. PubMed ID: 25881672
[TBL] [Abstract][Full Text] [Related]
19. [Use of rituximab in maintenance treatment of pemphigus: A retrospective series].
Barroil M; Girard C; Lerisson M; Negroni V; Bertrand AS; Pallure V; Bessis D; Guillot B; Dereure O
Ann Dermatol Venereol; 2020 Mar; 147(3):173-178. PubMed ID: 31955970
[TBL] [Abstract][Full Text] [Related]
20. First-line rituximab combined with short-term prednisone versus prednisone alone for the treatment of pemphigus (Ritux 3): a prospective, multicentre, parallel-group, open-label randomised trial.
Joly P; Maho-Vaillant M; Prost-Squarcioni C; Hebert V; Houivet E; Calbo S; Caillot F; Golinski ML; Labeille B; Picard-Dahan C; Paul C; Richard MA; Bouaziz JD; Duvert-Lehembre S; Bernard P; Caux F; Alexandre M; Ingen-Housz-Oro S; Vabres P; Delaporte E; Quereux G; Dupuy A; Debarbieux S; Avenel-Audran M; D'Incan M; Bedane C; Bénéton N; Jullien D; Dupin N; Misery L; Machet L; Beylot-Barry M; Dereure O; Sassolas B; Vermeulin T; Benichou J; Musette P;
Lancet; 2017 May; 389(10083):2031-2040. PubMed ID: 28342637
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
